Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710250 | 0.82 | HPGD (0.61) | HPGDSIGMAR1HDAC4ALDH1A1 | |
| SCHEMBL26816770 | 0.80 | FFAR1 (0.47) | HPGDSIGMAR1HDAC4ALDH1A1GPR88 | |
| SCHEMBL25773047 | 0.77 | CYP1A2 (0.52) | HPGDALDH1A1ROCK2GPR88 | |
| SCHEMBL25773046 | 0.77 | CYP1A2 (0.52) | HPGDALDH1A1ROCK2GPR88 | |
| SCHEMBL25773054 | 0.73 | IKBKB (0.45) | HPGDALDH1A1ROCK2 | |
| SCHEMBL25773057 | 0.73 | IKBKB (0.45) | HPGDALDH1A1ROCK2 | |
| SCHEMBL25773051 | 0.72 | ROCK2 (0.47) | HPGDALDH1A1ROCK2GPR88 | |
| SCHEMBL25773050 | 0.72 | ROCK2 (0.47) | HPGDALDH1A1ROCK2GPR88 | |
| SCHEMBL25773048 | 0.72 | ROCK2 (0.45) | ROCK2GPR88 | |
| SCHEMBL12026594 | 0.72 | ROCK2 (0.59) | ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | HPGD 3509/4885SIGMAR1 1803/4885KDM5A 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.